All In Biotech

Drug Trial Radar · NCT04139798

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 599 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

599

Actual

Start

Jul 20, 2020

Primary completion

Mar 12, 2021

Study completion Mar 12, 2021

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

Conditions

  • Dry Eye Disease (DED)

Interventions

  • NOV03Drug

    100% Perfluorohexyloctane

  • PlaceboDrug

    Saline solution (0.6% sodium chloride solution)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57Time frame: Assessed from Baseline to Day 57
  2. Change From Baseline of Dryness Score at Day 57Time frame: Assessed from Baseline to Day 57

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 124

    Birmingham, Alabama

  • Bausch Site 125

    Scottsdale, Arizona

  • Bausch Site 110

    Glendale, California

  • Bausch Site 121

    Long Beach, California

  • Bausch Site 102

    Mission Hills, California

  • Bausch Site 101

    Newport Beach, California

  • Bausch Site 116

    Rancho Cordova, California

  • 103

    Torrance, California

  • Bausch Site 123

    Torrance, California

  • Bausch Site 127

    Danbury, Connecticut

  • Bausch Site 129

    Fort Myers, Florida

  • Bausch Site 115

    Jacksonville, Florida

  • Bausch Site 106

    Largo, Florida

  • Bausch Site 117

    Tampa, Florida

  • Bausch Site 108

    Lake Villa, Illinois

  • Bausch Site 112

    Indianapolis, Indiana

  • Bausch Site 119

    Edgewood, Kentucky

  • Bausch Site 126

    Winchester, Massachusetts

  • Bausch Site 113

    Kansas City, Missouri

  • Bausch Site 111

    St Louis, Missouri

  • Bausch Site 128

    Slingerlands, New York

  • Bausch Site 114

    Raleigh, North Carolina

  • Bausch Site 122

    Cranberry Township, Pennsylvania

  • Bausch Site 107

    Memphis, Tennessee

  • Bausch Site 109

    Nashville, Tennessee

  • Bausch Site 120

    El Paso, Texas

  • Bausch Site 104

    Lakeway, Texas

  • Bausch Site 105

    Round Rock, Texas

  • Bausch Site 118

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.